NHS Inform Hepatitis Helpline
Open Mon to Fri 8am-10pm, Sat & Sun 9am-5pm:
0800 22 44 88
Find a service in your area - click here
Whats the difference ?
Welcome to the next instalment of Hepatitis Scotland's e-Bulletin. As the bulletin continues to evolve we are working on providing a mainly research focussed bulletin every second issue, to keep you up to date on recent national and international developments in treatment, including adjuncts as discussed in this issue, and support.
Hepatitis Scotland does not endorse products. However we do believe that if there is interest in new treatment or technologies then ways to decrease service costs should be explored. As the Accuvein technology appears to be of interest to a number of services, Hepatitis Scotland would like to highlight this with NSS National Procurement, as a way of negotiating down costs. Please email firstname.lastname@example.org if your service would like to register interest.
Lead Officer, Hepatitis Scotland
HCV testing for ALL American baby boomers (those born between 1945 and 1965) would identify 86% of that cohort who were chronically infected, according to a paper presented at the annual conference of the American Association for the Study of Liver Diseases (AASLD). This could prevent 82000 HCV related deaths in the US.
Hepatitis Scotland welcomes the appointment of George Valiotis as CEO of HIV Scotland. Hepatitis Scotland's Lead Officer Leon Wylie said," We look forward to working with George and continuing our work with his team. As Co-chairs of the Sexual Health and BBV Strategy voluntary sector network we will look at innovative ways of partnership working to enhance the effectiveness of voluntary sector input. I am sure George will be excellent to work with".
Together, studies recently conducted across the UK suggest that consistent participation in methadone maintenance treatment plus adequate access to fresh injecting equipment has prevented many hepatitis C infections. This evidence backs some of the core tenets of the Scottish Government's Phase 2 Hepatitis C action Plan.
(sourced from Drug and Alcohol Findings)
A new technology being trialled in Greater Glasgow and Clyde NHS could enhance patient experience when attending assessment and treatment at specialist clinics. This could potentially start to overcome patient fears about accessing specialist treatment and therefore lead to greater numbers coming forward for treatment.
Accuvein, which has been the subject of an STV and national newspaper story is a illumination technology that can show a real time map of a patients veins on the skin where venipuncture is about to take place, potentially elevating the likelihood of locating a vein that blood can be taken from. Laura Mathers, Blood Borne Virus Clinical Nurse Specialist Team Leader from the Brownlee Centre said," it is not always successful (approx 50%) but can be a very useful additional tool in identifying veins. This can lead to a better relationship with these patients who have often had bad experiences having blood taken in the past and those who are needle phobic". Laura added that over time it can save large amounts of staff time, equipment costs and lessen the number of unsuccessful laboratory reports, decreasing the need to recall patients for re-testing.
Coffee consumption may slow liver disease progression and increase the chances of success while undergoing treatment for chronic hepatitis C infection, but drinking three or more cups a day also appears to reduce the incidence of HCV treatment side effects by more than 80 percent amongst people with HIV and HCV.
(Sourced from hepmag.com)
A twelve-week course of Pharmasset’s once-daily experimental nucleotide analog PSI-7977, combined with ribavirin, cured 10 of 10 people living with genotype 2/3 hepatitis C virus (HCV) who used the regimen—without pegylated interferon—in a Phase II clinical trial.
On the back of this small but succesful trial Pharmasset has instituted Phase 3 trials of an Interferon-Free Program with PSI-7977 for HCV
- Three l studies planned to evaluate PSI-7977 400 mg QD plus ribavirin for 12 weeks in patients with HCV
- Anticipated US and EU marketing submissions in second half of 2013
PSI-7977 also has had success with Genotype 1 when used with combination therapy, getting clearance rates of 91% in the trial.
(Sourced from Hepmag.com)
Roughly 70 percent of people living with HIV and hepatitis C virus (HCV) coinfection have undetectable HCV viral loads after 24 weeks of treatment with either teleprevir or boceprevir plus pegylated interferon and ribavirin, according to interim results from two studies reported at two recent medical conferences.
An event in Glasgow on the 8th December, debating the film Raw Opium: Pain, Pleasure, Profits and the recommendations of the Global Commission on Drug Policy, will discuss dovetailing new approaches with the strengths of current drug strategy and practice.